Last reviewed · How we verify
Amlodipine+Benazepril
Amlodipine relaxes blood vessels by blocking calcium channels, while benazepril lowers blood pressure by inhibiting angiotensin-converting enzyme (ACE), together reducing hypertension through complementary pathways.
Amlodipine relaxes blood vessels by blocking calcium channels, while benazepril lowers blood pressure by inhibiting angiotensin-converting enzyme (ACE), together reducing hypertension through complementary pathways. Used for Hypertension.
At a glance
| Generic name | Amlodipine+Benazepril |
|---|---|
| Also known as | Amtrel® |
| Sponsor | TSH Biopharm Corporation Limited |
| Drug class | Calcium channel blocker + ACE inhibitor combination |
| Target | L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that prevents calcium influx into vascular smooth muscle cells, causing vasodilation. Benazepril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. The combination provides additive antihypertensive effects through these distinct mechanisms.
Approved indications
- Hypertension
Common side effects
- Headache
- Dizziness
- Fatigue
- Peripheral edema
- Cough
- Hyperkalemia
Key clinical trials
- Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets (PHASE1)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions (PHASE1)
- Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditions (PHASE1)
- Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg (PHASE1)
- Fed Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg (PHASE1)
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (PHASE3)
- ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine+Benazepril CI brief — competitive landscape report
- Amlodipine+Benazepril updates RSS · CI watch RSS
- TSH Biopharm Corporation Limited portfolio CI